Applied BioMath Assess Webinar Series

About the Event

Three webinars taking place Tuesday, October 25th

Applying model-informed drug discovery and development (MID3) early in development can reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. However, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data available at early stages can make modeling a challenge. For this reason, we developed Early Feasibility Assessment (EFA): a method for making effective dose predictions using mechanistic PK/PD models built from general biophysical principles and parameterized by data that is readily available early in drug discovery.  

Applied BioMath Assess™ is a point-and-click, MID3 software for performing EFA across various modalities. This webinar series will discuss scientific case studies demonstrating how you can quickly inform target selection, project clinical dose requirements, design a lead optimization funnel, and identify areas of program risk.  
 

Featured Webinars and Times

12:00PM - Checkpoint Inhibitors and TCEs

Title: Early Feasibility Analysis of Biotherapeutics: 

  • Checkpoint inhibitors: Is target engagement the whole story
  • Predicting on-target, off-tumor toxicity of Solitomab, an EpCAM/CD3 BiTE

2:00PM - Gene Therapy

Title: LNP-delivered mRNA for UGT1A1 replacement in Crigler-Najjar syndrome type 1 patients

4:00PM - Protein Degraders

Title: Guiding Target Selection and Lead Optimization for a PROTAC Targeted Protein Degrader

 

Register